Company profile: Oasmia
1.1 - Company Overview
Company description
- Provider of human and veterinary oncology drugs, developing, manufacturing, marketing and selling novel formulations of well-established cytostatics with improved properties, reduced side effects and expanded therapeutic use. Portfolio includes Paccal Vet (XR-17) for canine cancers, Cantrixil for blood cancer, Docetaxel micellar for prostate cancer, and XR-18 delivery technology.
Products and services
- Cantrixil: A development-stage oncology product for blood cancer, architected to offer new treatment options for hard-to-treat malignancies in hematologic settings
- Docetaxel micellar: A proprietary micellar formulation in development for prostate cancer, leveraging company technology to improve safety and efficacy in treatment
- Paccal Vet: A veterinary-grade oncology drug for dogs, formulated with XR-17 technology and specifically evaluated for splenic hemangiosarcoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oasmia
Avitide
HQ: United States
Website
- Description: Provider of customized affinity purification solutions for biopharmaceuticals, including AVIPure affinity resins for custom and platform use, proprietary solutions to improve bioprocessing and manufacturing, a flexible, scalable commercial resin supply supported by ISO 9001:2015 operations, regulatory support and documentation, and AVIPure-AAV8 for single-step AAV8 purification with high yield, purity, and capacity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avitide company profile →
Altar
HQ: France
Website
- Description: Provider of biotechnology solutions in automated fluidics, developing and operating proprietary technologies that bring microbes to performance suitable for commercial use. Serves customers leveraging microorganisms to produce food, feed, flavors & fragrances, cosmetics, and fuels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altar company profile →
BBI Solutions
HQ: United Kingdom
Website
- Description: Provider of raw materials and test technology platforms for the diagnostics market, offering monoclonal and polyclonal antibodies for antigen identification, custom antibody manufacturing and conjugation services, matched antibody pairs for capture and detection, and Novarum, a smartphone platform that turns a phone into a diagnostic test reader to read and share rapid test results at the point of care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BBI Solutions company profile →
PowderMed
HQ: United Kingdom
Website
- Description: Provider of Particle Mediated Epidermal Delivery (PMED) technology and vaccines for chronic infectious diseases and cancer, using DNA-coated gold particles delivered by a needle-free injection device to stimulate specific T cell immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PowderMed company profile →
Nanosphere
HQ: United States
Website
- Description: Provider of a nanotechnology-based molecular diagnostics platform and clinical tests for genomic and protein testing and analysis. Instruments use microfluidics to pull DNA and proteins, delivering results in hours rather than days or weeks, with sensitivity two to three times higher than common hospital lab tests and much simpler.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanosphere company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oasmia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oasmia
2.2 - Growth funds investing in similar companies to Oasmia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oasmia
4.2 - Public trading comparable groups for Oasmia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →